

COURSE FACULTY, IAS–USA STAFF, SCIENTIFIC LEADERSHIP BOARD, AND GOVERNANCE BOARD

FINANCIAL RELATIONSHIPS WITH INELIGIBLE COMPANIES

In the interest of maintaining the independence of its CME activities and in accordance with the policies of the Accreditation Council for Continuing Medical Education (ACCME), the IAS–USA requires all persons with control of content (eg, course faculty, Scientific Leadership Board, Governance Board, and program staff) to disclose any financial relationships that have had with ineligible companies (previously defined as “commercial interests”) within the previous 24 months. Any real or apparent conflicts of interest of those parties are resolved prior to the CME activity being delivered and have been mitigated. Individuals who refuse to disclose financial relationships may not participate in an IAS–USA CME activity. The **ACCME defines ineligible companies** as “those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.” Below are the financial interests that faculty members of this course have had within the past 24 months. View the [Faculty Financial Disclosure Policy](#).

STATE-OF-THE-ART UPDATE ON LONG COVID: PATHOGENESIS, MANAGEMENT, CLINICAL TRIAL UPDATES, AND PATIENT PERSPECTIVE – JUNE 22, 2023

Course Presenters	
Annie Antar, MD PhD Assistant Professor The Johns Hopkins University School of Medicine Baltimore, Maryland	Dr Antar has no relevant financial relationships with ineligible companies to disclose. (Updated May 31, 2023)
Roger Paredes, MD, PhD Head, Department of Infectious Diseases and IrsiCaixa AIDS Research Institute Hospital Germans Trias i Pujol Badalona, Spain	Dr Paredes served on advisory boards for Gilead Sciences, Inc, Pfizer, Inc, Roche Therapeutics, MSD, GSK, ViiV Healthcare, Eli Lilly and Company, and Atea Pharmaceuticals, Inc. He has had research grants paid to his institution from MSD, ViiV Healthcare, Gilead Sciences, and PharmaMar. (Updated June 8, 2023)
Jeffrey N. Siegelman, MD Associate Professor of Emergency Medicine Emory University School of Medicine Atlanta, Georgia	Dr Siegelman has no relevant financial relationships with ineligible companies to disclose. (Updated June 5, 2023)
Tiffany Walker, MD Assistant Professor Emory University School of Medicine Atlanta, Georgia	Dr Walker has no relevant financial relationships with ineligible companies to disclose. (Updated June 7, 2023)
Kanecia Zimmerman, MD, PhD, MPH Associate Professor Duke University Durham, North Carolina	Dr Zimmerman received grant funding from the Biogen Foundation to support a summer research training. (Updated June 5, 2023)

IAS–USA CME Planners and Reviewers	
Judith S. Currier, MD Professor of Medicine Chief, Division of Infectious Disease Co-Director, Clinical AIDS Research and Education Center Michael and Sue Steinberg Chair in Global AIDS Research David Geffen School of Medicine University of California Los Angeles	Dr Currier has served on the advisory board for Merck & Co, Inc. (Updated March 16, 2023)
Distinguished Professor of Medicine Interim Dean, Emory University School of Medicine Interim Chief Academic Officer Emory University Atlanta, Georgia	Dr Del Rio has served as a scientific advisor for Resverlogix. (Updated March 31, 2023)

Donna M. Jacobsen
Executive Director/President
IAS–USA

Ms Jacobsen has no relevant financial affiliations with ineligible companies to disclose. (Updated June 16, 2023)

IAS–USA Boards

The nonstaff members of the [IAS–USA Scientific Advisory Board](#) and [Governance Board](#) are not compensated for their roles in governing and overseeing the IAS–USA and content development. Please see the About page on the IAS–USA website for information about board members and a link to up-to-date financial disclosure information.